2025-05-11 - Analysis Report
## Recursion Pharmaceuticals Inc (RXRX) Stock Review

**0) Executive Summary:** RXRX, a clinical-stage biopharmaceutical company leveraging AI to discover and develop novel treatments, shows significant underperformance compared to the S&P 500 (VOO).  Negative returns, declining key financial metrics, and weak technical indicators paint a concerning picture.  The high negative expected return suggests significant risk.

**1) Performance Comparison:**

Recursion Pharmaceuticals Inc (RXRX) is a clinical-stage biopharmaceutical company using artificial intelligence (AI) to discover and develop new drugs.

* **RXRX Cumulative Return:** -59.08%
* **VOO (S&P 500) Cumulative Return:** 19.65%
* **Return Difference:** -78.7%  This places RXRX at the 1.0 percentile of its historical performance relative to the S&P 500 (based on the provided relative divergence).  This indicates extreme underperformance.

**Alpha/Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2021-2023  | 5.0% | 73.6% | -12.0% | 4.0 |
| 2022-2024  | 0.0% | 73.6% | -22.0% | 2.7 |
| 2023-2025  | -8.0% | 73.6% | -26.0% | 1.8 |

The negative alpha consistently shows underperformance relative to the market benchmark.  The high beta (above 1) indicates high volatility and significant sensitivity to market movements. The decreasing market capitalization is also a negative signal.


**2) Recent Price Movement:**

* **Closing Price:** $4.39
* **Last Market Change:** -1.37%  (a slight decrease)
* **5-Day Moving Average:** $4.64
* **20-Day Moving Average:** $5.31
* **60-Day Moving Average:** $6.34

The price is below all three moving averages, suggesting a downtrend.


**3) Technical Indicators:**

* **Market Risk Indicator (MRI):** 0.37 (Low Risk) -  While the MRI suggests low risk, this contradicts the severe negative returns and other indicators.
* **RSI:** 31.38 (Oversold) -  Suggests the stock may be oversold, but this doesn't automatically imply a bullish reversal.
* **PPO:** -2.14 (Bearish) - A negative PPO indicates bearish momentum.
* **20-Day Relative Divergence Change:** -5.0% (Short-term downtrend)
* **Expected Return:** -3719.7% -  This extremely negative expected return, especially in relation to the S&P 500, indicates significant risk.  It is highly unlikely that a long-term investment would outperform the S&P 500 based on this data.  The expected return should be reviewed; an error might have occurred.


**4) Recent Earnings Analysis:**

| Date       | EPS    | Revenue      |
|------------|--------|--------------|
| 2025-05-05 | -0.5   | $0.01 B      |
| 2024-11-06 | -0.34  | $0.03 B      |
| 2024-08-08 | -0.4   | $0.01 B      |
| 2024-05-09 | -0.39  | $0.01 B      |
| 2025-05-05 | -0.39  | $0.01 B      |


Consistent negative EPS and low revenue growth demonstrate the company's financial struggles.


**5) Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-03-31 | $0.01B | -47.31%      |
| 2024-12-31 | $0.00B | -183.62%     |
| 2024-09-30 | $0.03B | 53.69%       |
| 2024-06-30 | $0.01B | 36.14%       |
| 2024-03-31 | $0.01B | 17.23%       |


**Capital and Profitability:**

| Quarter | Equity | ROE     |
|---------|---------|---------|
| 2025-03-31 | $0.93B | -21.68% |
| 2024-12-31 | $1.03B | -17.29% |
| 2024-09-30 | $0.52B | -18.27% |
| 2024-06-30 | $0.58B | -16.69% |
| 2024-03-31 | $0.40B | -22.78% |


Negative profit margins and ROE across multiple quarters indicate significant financial challenges.  The erratic nature of the figures suggests underlying volatility.


**6) Overall Analysis:**

RXRX exhibits substantial underperformance relative to the S&P 500, displaying negative returns, declining financials, and weak technical indicators. The high negative expected return (-3719.7%) is particularly concerning and requires review as such a result is improbable.  The company's financial health is questionable, showing consistent losses and low revenue.  Based on the provided data, RXRX presents a high-risk investment with a very low probability of outperforming the market.  Further investigation into the company's pipeline, strategic direction, and the validity of the -3719.7% expected return figure is highly recommended before considering any investment.
